RO 465934
Latest Information Update: 28 Nov 2006
Price :
$50 *
At a glance
- Originator Roche
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Muscarinic M2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 25 Aug 1998 No-Development-Reported for Alzheimer's disease (Unknown route)
- 29 Aug 1996 New profile
- 29 Aug 1996 Preclinical development for Alzheimer's disease (Unknown route)